Vivus is a biopharmaceutical company engaged in commercializing and developing therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Co.'s drug, Qsymia™ (phentermine and topiramate extended-release) has been approved for the treatment of obesity in the presence of at least one weight-related comorbidity. Co.'s drug, STENDRA™, or avanafil, has been approved for the treatment of erectile dysfunction. In addition, Co. has licensed the rights to other investigational drug candidates to treat various diseases and medical conditions. Co. also sponsors early stage clinical trials at various research institutions.
VVUS — Key Stats (updated Monday, March 3, 10:21 AM)
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.